4//SEC Filing
INTERCEPT PHARMACEUTICALS INC 4
Accession 0001144204-14-001504
CIK 0001270073operating
Filed
Jan 8, 7:00 PM ET
Accepted
Jan 9, 9:30 PM ET
Size
5.9 KB
Accession
0001144204-14-001504
Insider Transaction Report
Form 4
TALLARIGO LORENZO
Director
Transactions
- Sale
Common Stock
2014-01-07$67.41/sh−1,839$123,967→ 1,640 total
Holdings
- 5,938,890(indirect: See Footnote)
Common Stock
Footnotes (2)
- [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 18, 2013.
- [F2]Held by Genextra S.p.A. Dr. Tallarigo is the chief executive officer of Genextra S.p.A. and, in such capacity, Dr. Tallarigo exercises voting control over the shares of common stock owned by Genextra S.p.A. and investment control over such shares as authorized by the board of directors of Genextra S.p.A. Dr. Tallarigo disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.
Documents
Issuer
INTERCEPT PHARMACEUTICALS INC
CIK 0001270073
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001270073
Filing Metadata
- Form type
- 4
- Filed
- Jan 8, 7:00 PM ET
- Accepted
- Jan 9, 9:30 PM ET
- Size
- 5.9 KB